Literature DB >> 10845920

CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

P Chu1, W G Wierda, T J Kipps.   

Abstract

Cytotoxic T lymphocytes (CTLs) can kill target cells by the granule/exocytosis pathway or the Fas-mediated apoptosis pathway. The sensitivity of chronic lymphocytic leukemia (CLL) B cells to CTL-mediated apoptosis before and after CD40 activation was examined. Resting or CD40-activated CLL cells were found to be equally sensitive to class I-restricted CTL-mediated killing. Despite expressing CD95, the CD40-activated CLL target cells were found to be resistant to apoptosis induced by CH11, an IgM CD95 monoclonal antibody (mAb). Consistent with this, inhibitors of caspases, which are involved in the Fas-induced apoptotic pathway (eg, N-carbobenzoxy-Val-Ala-Asp fluoromethyl ketone [z-VAD-fmk]), were unable to block destruction of CLL target cells by CTL. In addition, preincubation of the effector T cells with the anti-Fas ligand mAb NOK-2 failed to inhibit their subsequent ability to kill CLL target cells. On the other hand, CTL activity was blocked by inhibitors of the granule exocytosis pathway such as ethylene-glyco-tetra-acetic acid or concanamycin A. These results indicate that CD40 activation does not impair the sensitivity of CLL cells to Fas-independent CTL-mediated apoptosis. (Blood. 2000;95:3853-3858)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845920

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

Authors:  N Porakishvili; T Roschupkina; T Kalber; A P Jewell; K Patterson; K Yong; P M Lydyard
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

3.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

4.  Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy.

Authors:  Diahnn Futalan; Chien-Tze Huang; Ingo G H Schmidt-Wolf; Marie Larsson; Davorka Messmer
Journal:  Mol Med       Date:  2011-06-01       Impact factor: 6.354

5.  A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

Authors:  W G Wierda; J E Castro; R Aguillon; D Sampath; A Jalayer; J McMannis; C E Prussak; M Keating; T J Kipps
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

6.  Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.

Authors:  Peter Chu; Dieter Deforce; Irene M Pedersen; Youngsoo Kim; Shinichi Kitada; John C Reed; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Authors:  Jessie-F Fecteau; Laura G Corral; Emanuela M Ghia; Svetlana Gaidarova; Diahnn Futalan; Ila Sri Bharati; Brian Cathers; Maria Schwaederlé; Bing Cui; Antonia Lopez-Girona; Davorka Messmer; Thomas J Kipps
Journal:  Blood       Date:  2014-07-02       Impact factor: 22.113

8.  Chronic lymphocytic leukemia: an update on biology and treatment.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.945

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.